Publications by authors named "John Golin"

Claim this Profile
S
Second-site suppressor mutations reveal connection between the drug-binding pocket and nucleotide-binding domain 1 of human P-glycoprotein (ABCB1).
Megumi Murakami, Andaleeb Sajid, Sabrina Lusvarghi, Stewart R Durell, Biebele Abel, John Golin

Drug Resist Updat· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pdr5: A master of asymmetry.
John Golin, Lutz Schmitt

Drug Resist Updat· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Residues forming the gating regions of asymmetric multidrug transporter Pdr5 also play roles in conformational switching and protein folding.
Maryam Alhumaidi, Lea-Marie Nentwig, Hadiar Rahman, Lutz Schmitt, Andrew Rudrow, John Golin

J Biol Chem· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Residues forming the gating regions of asymmetric multidrug transporter Pdr5 also play roles in conformational switching and protein folding.
Maryam Alhumaidi, Lea-Marie Nentwig, Hadiar Rahman, Lutz Schmitt, Andrew Rudrow, John Golin

J Biol Chem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How fungal multidrug transporters mediate hyper resistance through DNA amplification and mutation.
Atanu Banerjee, Hadiar Rahman, Rajendra Prasad, John Golin

Mol Microbiol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonsynonymous Mutations in Linker-2 of the Pdr5 Multidrug Transporter Identify a New RNA Stability Element.
Hadiar Rahman, Andrew Rudrow, Joshua Carneglia, Sister Stephen Patrick Joly, Dante Nicotera, John Golin

G3 (Bethesda)· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An A666G mutation in transmembrane helix 5 of the yeast multidrug transporter Pdr5 increases drug efflux by enhancing cooperativity between transport sites.
Nidhi Arya, Hadiar Rahman, Andrew Rudrow, Manuel Wagner, Lutz Schmitt, John Golin

Mol Microbiol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust, pleiotropic drug resistance 5 (Pdr5)-mediated multidrug resistance is vigorously maintained in Saccharomyces cerevisiae cells during glucose and nitrogen limitation.
Hadiar Rahman, Joshua Carneglia, Molly Lausten, Michael Robertello, John Choy, John Golin

FEMS Yeast Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The multidrug transporter Pdr5 on the 25th anniversary of its discovery: an important model for the study of asymmetric ABC transporters.
John Golin, Suresh V Ambudkar

Biochem J· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence for a molecular diode-based mechanism in a multispecific ATP-binding cassette (ABC) exporter: SER-1368 as a gatekeeping residue in the yeast multidrug transporter Pdr5.
Jitender Mehla, Robert Ernst, Rachel Moore, Adina Wakschlag, Mary Kate Marquis, John Golin

J Biol Chem· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The deviant ATP-binding site of the multidrug efflux pump Pdr5 plays an active role in the transport cycle.
Christopher Furman, Jitender Mehla, Neeti Ananthaswamy, Nidhi Arya, Bridget Kulesh, John Golin

J Biol Chem· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The transmission interface of the Saccharomyces cerevisiae multidrug transporter Pdr5: Val-656 located in intracellular loop 2 plays a major role in drug resistance.
Marianne T Downes, Jitender Mehla, Neeti Ananthaswamy, Adina Wakschlag, Micheala Lamonde, John Golin

Antimicrob Agents Chemother· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The signaling interface of the yeast multidrug transporter Pdr5 adopts a cis conformation, and there are functional overlap and equivalence of the deviant and canonical Q-loop residues.
Neeti Ananthaswamy, Robert Rutledge, Zuben E Sauna, Suresh V Ambudkar, Elliot Dine, John Golin

Biochemistry· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations define cross-talk between the N-terminal nucleotide-binding domain and transmembrane helix-2 of the yeast multidrug transporter Pdr5: possible conservation of a signaling interface for coupling ATP hydrolysis to drug transport.
Zuben E Sauna, Sherry Supernavage Bohn, Robert Rutledge, Michael P Dougherty, Susan Cronin, John Golin

J Biol Chem· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pdr5-mediated multidrug resistance requires the CPY-vacuolar sorting protein Vps3: are xenobiotic compounds routed from the vacuole to plasma membrane transporters for efflux?
Robert M Rutledge, Michel Ghislain, J Michael Mullins, Cedric Pety de Thozée, John Golin

Mol Genet Genomics· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete inhibition of the Pdr5p multidrug efflux pump ATPase activity by its transport substrate clotrimazole suggests that GTP as well as ATP may be used as an energy source.
John Golin, Zachary N Kon, Chung-Pu Wu, Justin Martello, Leanne Hanson

Biochemistry· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The yeast Pdr5p multidrug transporter: how does it recognize so many substrates?
John Golin, Suresh V Ambudkar, Leopold May

Biochem Biophys Res Commun· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcellular trafficking of the yeast plasma membrane ABC transporter, Pdr5, is impaired by a mutation in the N-terminal nucleotide-binding fold.
Cédric Pety de Thozée, Susan Cronin, Agnieszka Goj, John Golin, Michel Ghislain

Mol Microbiol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of hydrogen bond acceptor groups in the interaction of substrates with Pdr5p, a major yeast drug transporter.
Leanne Hanson, Leopold May, Pamela Tuma, James Keeven, Patrick Mehl, John Golin

Biochemistry· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux.
John Golin, Suresh V Ambudkar, Michael M Gottesman, Asif Dominic Habib, John Sczepanski

J Biol Chem· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PDR2 Gain-of-function mutations eliminate the need for Pdr1 and require the UBP6 product for resistance to translational inhibitors.
James Keeven, Daejin Ko, Joshua Shallom, Beth Uccelini, John Golin

Curr Genet· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis